These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Prostate Cancer Screening in a New Era of Genetics. Cheng HH; Pritchard CC; Montgomery B; Lin DW; Nelson PS Clin Genitourin Cancer; 2017 Dec; 15(6):625-628. PubMed ID: 28697982 [TBL] [Abstract][Full Text] [Related]
5. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. Mitra AV; Bancroft EK; Barbachano Y; Page EC; Foster CS; Jameson C; Mitchell G; Lindeman GJ; Stapleton A; Suthers G; Evans DG; Cruger D; Blanco I; Mercer C; Kirk J; Maehle L; Hodgson S; Walker L; Izatt L; Douglas F; Tucker K; Dorkins H; Clowes V; Male A; Donaldson A; Brewer C; Doherty R; Bulman B; Osther PJ; Salinas M; Eccles D; Axcrona K; Jobson I; Newcombe B; Cybulski C; Rubinstein WS; Buys S; Townshend S; Friedman E; Domchek S; Ramon Y Cajal T; Spigelman A; Teo SH; Nicolai N; Aaronson N; Ardern-Jones A; Bangma C; Dearnaley D; Eyfjord J; Falconer A; Grönberg H; Hamdy F; Johannsson O; Khoo V; Kote-Jarai Z; Lilja H; Lubinski J; Melia J; Moynihan C; Peock S; Rennert G; Schröder F; Sibley P; Suri M; Wilson P; Bignon YJ; Strom S; Tischkowitz M; Liljegren A; Ilencikova D; Abele A; Kyriacou K; van Asperen C; Kiemeney L; ; Easton DF; Eeles RA BJU Int; 2011 Jan; 107(1):28-39. PubMed ID: 20840664 [TBL] [Abstract][Full Text] [Related]
6. Personalized prostate cancer screening among men with high risk genetic predisposition- study protocol for a prospective cohort study. Margel D; Benjaminov O; Ozalvo R; Shavit Grievink L; Kedar I; Yerushalmi R; Ben-Aharon I; Neiman V; Yossepowitch O; Kedar D; Levy Z; Shohat M; Brenner B; Baniel J; Rosenbaum E BMC Cancer; 2014 Jul; 14():528. PubMed ID: 25047061 [TBL] [Abstract][Full Text] [Related]
7. Male BRCA mutation carriers: clinical characteristics and cancer spectrum. Ibrahim M; Yadav S; Ogunleye F; Zakalik D BMC Cancer; 2018 Feb; 18(1):179. PubMed ID: 29433453 [TBL] [Abstract][Full Text] [Related]
8. Management of a Prostate Cancer Patient With Inherited Germline BRCA1 and BRCA2 Mutations: A Case Report. Hemal S; DeWitt-Foy M; Klein EA Urology; 2021 Jul; 153():129-131. PubMed ID: 33556450 [TBL] [Abstract][Full Text] [Related]
9. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer. Hamel N; Kotar K; Foulkes WD BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837 [TBL] [Abstract][Full Text] [Related]
10. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. Oh M; Alkhushaym N; Fallatah S; Althagafi A; Aljadeed R; Alsowaida Y; Jeter J; Martin JR; Babiker HM; McBride A; Abraham I Prostate; 2019 Jun; 79(8):880-895. PubMed ID: 30900310 [TBL] [Abstract][Full Text] [Related]
12. Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. Nyberg T; Frost D; Barrowdale D; Evans DG; Bancroft E; Adlard J; Ahmed M; Barwell J; Brady AF; Brewer C; Cook J; Davidson R; Donaldson A; Eason J; Gregory H; Henderson A; Izatt L; Kennedy MJ; Miller C; Morrison PJ; Murray A; Ong KR; Porteous M; Pottinger C; Rogers MT; Side L; Snape K; Walker L; Tischkowitz M; Eeles R; Easton DF; Antoniou AC Eur Urol; 2020 Jan; 77(1):24-35. PubMed ID: 31495749 [TBL] [Abstract][Full Text] [Related]
13. Screening, Active Surveillance, and Treatment of Localized Prostate Cancer Among Carriers of Germline BRCA Mutations. Halstuch D; Ber Y; Margel D Eur Urol Focus; 2020 Mar; 6(2):212-214. PubMed ID: 31147265 [TBL] [Abstract][Full Text] [Related]
14. Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers. Shimada S; Yoshida R; Nakashima E; Kitagawa D; Gomi N; Horii R; Takeuchi S; Ashihara Y; Kita M; Akiyama F; Ohno S; Saito M; Arai M Breast Cancer; 2019 Nov; 26(6):846-851. PubMed ID: 30980249 [TBL] [Abstract][Full Text] [Related]
16. Elevated expression of Ki-67 identifies aggressive prostate cancers but does not distinguish BRCA1 or BRCA2 mutation carriers. Mitra AV; Jameson C; Barbachano Y; Sodha N; Kote-Jarai Z; Javed A; Bancroft E; Fletcher A; Cooper C; Peock S; ; Easton D; Eeles R; Foster CS Oncol Rep; 2010 Feb; 23(2):299-305. PubMed ID: 20043088 [TBL] [Abstract][Full Text] [Related]
17. Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms. Gulati R; Cheng HH; Lange PH; Nelson PS; Etzioni R Cancer Epidemiol Biomarkers Prev; 2017 Feb; 26(2):222-227. PubMed ID: 27742670 [TBL] [Abstract][Full Text] [Related]
18. Male BRCA1 and BRCA2 mutation carriers: a pilot study investigating medical characteristics of patients participating in a prostate cancer prevention clinic. Horsburgh S; Matthew A; Bristow R; Trachtenberg J Prostate; 2005 Oct; 65(2):124-9. PubMed ID: 15880530 [TBL] [Abstract][Full Text] [Related]
19. Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations. Bancroft EK; Saya S; Page EC; Myhill K; Thomas S; Pope J; Chamberlain A; Hart R; Glover W; Cook J; Rosario DJ; Helfand BT; Hutten Selkirk C; Davidson R; Longmuir M; Eccles DM; Gadea N; Brewer C; Barwell J; Salinas M; Greenhalgh L; Tischkowitz M; Henderson A; Evans DG; Buys SS; ; ; Eeles RA; Aaronson NK BJU Int; 2019 Feb; 123(2):284-292. PubMed ID: 29802810 [TBL] [Abstract][Full Text] [Related]